Medical/Pharmaceuticals
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
* Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines TORONTO, Jan. 21, 2026 /PRNewswire/ -- Daiichi Sankyo (TSE: 4568) has further established its presence in Canada with the official opening of its permanent headquarters ...
2026-01-21 21:00
6962
Sisram Medical Partners with Sinmait Medical Technology to Build Next-Generation Manufacturing and Innovation Hub in China
HONG KONG, Jan. 21, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced th...
2026-01-21 19:08
14802
HistoIndex Partners with Houston Research Institute to Expand Advanced MASH Diagnostic Services
SINGAPORE, Jan. 21, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced a strategic partnership with Houston Research Institute (HRI). HRI is a leading research institute focused on conducting clinical trials in hepatology a...
2026-01-21 11:00
5838
CLEARLAB CONTACT LENSES AND LENS CARE PRODUCTS RECEIVE COMBINED MDSAP, ISO13485 AND EU MDR CERTIFICATION FROM DNV
Parallel audit streamlines certification and speeds up access to global markets SINGAPORE, Jan. 21, 2026 /PRNewswire/ -- DNV, the independent global assurance and risk management provider, has certified contact lenses and multi-purpose lens care solutions from Clearlab in accordance with the Medi...
2026-01-21 10:00
7140
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ -- Gene Solutions
2026-01-21 09:00
8342
Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy
* Japan's Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases * Enhances strong global regulatory momentum, ...
2026-01-21 06:00
6519
Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand
DEERFIELD, Ill., Jan. 21, 2026 /PRNewswire/ -- Baxter Healthcare is pleased to share the growing success of the room temperature storage configuration of Hemopatch Sealing Hemostat, launched earlier, this Summer, across Australia and New Zealand. Since its introduction, the product has been met w...
2026-01-21 03:00
5823
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broaden...
2026-01-21 01:55
5112
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product,strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more LOS ANGELES and MELBOURNE, Australia, Jan. 20, 2026 /PRNewswire/ -- 4DMedical, the lead...
2026-01-20 19:00
7620
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent t...
2026-01-20 17:00
7336
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights * Full-year (FY) 2...
2026-01-20 15:16
10590
cpThrive: A first-of-its-kind digital guide to help identify evidence-based cerebral palsy treatments
SYDNEY, Jan. 20, 2026 /PRNewswire/ -- Cerebral Palsy Alliance, The University of Sydney, and CSIRO, Australia's national science agency, have commissioned Miroma Project Factory to deliver a groundbreaking mobile app that helps people with cerebral palsy (CP), their carers, and clinicians underst...
2026-01-20 13:46
5774
AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities
HONG KONG, Jan. 20, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative 20-valent pneumococcal conjugate vaccine, which has recently received clinical trial approval from the ...
2026-01-20 08:23
5625
Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (...
2026-01-20 06:15
6301
Sakai Clinic 62 Founder & Medical Director Mari Sakai Holds Dialogue with Peter Nobel, Chairman of the Nobel Sustainability Trust, Declaring Global Leadership as a Pioneer of Medical Sustainability
TOKYO, Jan. 20, 2026 /PRNewswire/ -- Sakai Clinic 62 (Location: Shibuya-ku, Tokyo; Founder & Medical Director: Mari Sakai) announces that Dr. Mari Sakai held a dialogue with Mr. Peter Nobel, Chairman of the Nobel Sustainability Trust (NST), to discuss the international promotion of sustainability...
2026-01-20 00:00
6282
Ageing, smoking, oral bacteria and genetic mutations linked to higher stomach cancer risk
* Duke-NUS and NUHS scientists uncover a complex web of genetic, age-related and microbial factors that increase the risk of stomach cancer. * Age-related blood cell mutations may trigger early changes in the stomach lining, offering new insights into how cancer risk builds over time and unde...
2026-01-19 20:07
8072
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: * D3S‑003 — ...
2026-01-19 09:00
6718
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of theProstate Avoidance Stratification Study), a Phase 3 trial ...
2026-01-17 03:21
5457
Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-01-16 09:00
9257
Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference
CHENGDU, China, Jan. 16, 2026 /PRNewswire/ -- From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990....
2026-01-16 02:30
12861
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 294 media titles]
2026-08-10 19:12
MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026
[Picked up by 293 media titles]
2026-08-11 19:03Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
14603
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
14347